Researchers at Penn Medicine found that women taking GLP-1 receptor agonist drugs had a lower incidence of breast cancer diagnoses [1].
The findings suggest that medications commonly used for weight loss and diabetes may provide protective effects against certain malignancies. Because these drugs are widely prescribed, the potential for cancer prevention could influence future clinical guidelines and patient care.
The observational study tracked more than 111,000 women between the ages of 45 and 80 [1]. Data indicated that the relative risk of developing breast cancer was lower for those using the medications, with reports ranging from about 30% [1] to 35% [2] lower risk.
Despite the relative percentage drop, some experts highlight the small absolute difference in diagnosis rates. The study recorded a 1.6% diagnosis rate in women on GLP-1 drugs compared to 2.3% in women not using the medications [3].
Researchers in Philadelphia said these results may be tied to the hormonal or metabolic effects of the drugs [4]. Some analysts said the findings add to a growing body of research that could position these medications as useful cancer-prevention tools [4].
Other medical experts said the difference is less than 1% and does not prove that the drugs prevent cancer [3]. Because the study was observational, it cannot establish a direct cause-and-effect relationship between the medication and the lower cancer rates [3, 4].
“Women taking GLP-1 receptor agonist drugs had a lower incidence of breast cancer diagnoses.”
While the relative risk reduction appears significant, the narrow gap in absolute diagnosis rates suggests the clinical impact may be modest. The study indicates a correlation rather than causation, meaning further randomized controlled trials are necessary to determine if GLP-1 drugs actively prevent breast cancer or if the result is linked to other metabolic improvements associated with weight loss.
